Selected research
Industry Research
Mesalamine API Industry Research Report 2026
Market perspective
The global Mesalamine API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Mesalamine API is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Mesalamine API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Mesalamine API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Mesalamine API include , among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Mesalamine API market in revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Mesalamine API.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mesalamine API Market by Company
Cambrex Corporation
Chemi SpA
Corden Pharma Bergamo
CTX Lifescience
Divis Laboratories
Erregierre SpA
Ipca Laboratories
Ishita Active Pharma Ingredients
Lasa Loboratory
PharmaZell
Syntese A/S
Hangzhou Brother
Lianyungang Fengheng Biopharm
YC Biotech (Jiangsu)
Mesalamine API Segment by Type
Purity ≥ 99%
Purity ≥ 98%
Purity ≥ 97%
Mesalamine API Segment by Application
Suppository
Tablets
Granule
Capsules
Enema
Others
Mesalamine API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mesalamine API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mesalamine API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mesalamine API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mesalamine API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mesalamine API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mesalamine API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Purity ≥ 99%
- Purity ≥ 98%
- Purity ≥ 97%
Applications
- Suppository
- Tablets
- Granule
- Capsules
- Enema
- Others
Companies covered
- Cambrex Corporation
- Chemi SpA
- Corden Pharma Bergamo
- CTX Lifescience
- Divis Laboratories
- Erregierre SpA
- Ipca Laboratories
- Ishita Active Pharma Ingredients
- Lasa Loboratory
- PharmaZell
- Syntese A/S
- Hangzhou Brother
- Lianyungang Fengheng Biopharm
- YC Biotech (Jiangsu)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Mesalamine API by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.2.2 Purity ≥ 99%
- 2.2.3 Purity ≥ 98%
- 2.2.4 Purity ≥ 97%
- 2.3 Mesalamine API by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Suppository
- 2.3.3 Tablets
- 2.3.4 Granule
- 2.3.5 Capsules
- 2.3.6 Enema
- 2.3.7 Others
- 2.4 Global Market Growth Prospects
- 2.4.1 Global Mesalamine API Production Value Estimates and Forecasts (2021-2032)
- 2.4.2 Global Mesalamine API Production Capacity Estimates and Forecasts (2021-2032)
- 2.4.3 Global Mesalamine API Production Estimates and Forecasts (2021-2032)
- 2.4.4 Global Mesalamine API Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mesalamine API Production by Manufacturers (2021-2026)
- 3.2 Global Mesalamine API Production Value by Manufacturers (2021-2026)
- 3.3 Global Mesalamine API Average Price by Manufacturers (2021-2026)
- 3.4 Global Mesalamine API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Mesalamine API Key Manufacturers, Manufacturing Sites & Headquarters
- 3.6 Global Mesalamine API Manufacturers, Product Type & Application
- 3.7 Global Mesalamine API Manufacturers Established Date
- 3.8 Global Mesalamine API Market CR5 and HHI
- 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Cambrex Corporation
- 4.1.1 Cambrex Corporation Mesalamine API Company Information
- 4.1.2 Cambrex Corporation Mesalamine API Business Overview
- 4.1.3 Cambrex Corporation Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.1.4 Cambrex Corporation Product Portfolio
- 4.1.5 Cambrex Corporation Recent Developments
- 4.2 Chemi SpA
- 4.2.1 Chemi SpA Mesalamine API Company Information
- 4.2.2 Chemi SpA Mesalamine API Business Overview
- 4.2.3 Chemi SpA Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.2.4 Chemi SpA Product Portfolio
- 4.2.5 Chemi SpA Recent Developments
- 4.3 Corden Pharma Bergamo
- 4.3.1 Corden Pharma Bergamo Mesalamine API Company Information
- 4.3.2 Corden Pharma Bergamo Mesalamine API Business Overview
- 4.3.3 Corden Pharma Bergamo Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.3.4 Corden Pharma Bergamo Product Portfolio
- 4.3.5 Corden Pharma Bergamo Recent Developments
- 4.4 CTX Lifescience
- 4.4.1 CTX Lifescience Mesalamine API Company Information
- 4.4.2 CTX Lifescience Mesalamine API Business Overview
- 4.4.3 CTX Lifescience Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.4.4 CTX Lifescience Product Portfolio
- 4.4.5 CTX Lifescience Recent Developments
- 4.5 Divis Laboratories
- 4.5.1 Divis Laboratories Mesalamine API Company Information
- 4.5.2 Divis Laboratories Mesalamine API Business Overview
- 4.5.3 Divis Laboratories Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.5.4 Divis Laboratories Product Portfolio
- 4.5.5 Divis Laboratories Recent Developments
- 4.6 Erregierre SpA
- 4.6.1 Erregierre SpA Mesalamine API Company Information
- 4.6.2 Erregierre SpA Mesalamine API Business Overview
- 4.6.3 Erregierre SpA Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.6.4 Erregierre SpA Product Portfolio
- 4.6.5 Erregierre SpA Recent Developments
- 4.7 Ipca Laboratories
- 4.7.1 Ipca Laboratories Mesalamine API Company Information
- 4.7.2 Ipca Laboratories Mesalamine API Business Overview
- 4.7.3 Ipca Laboratories Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.7.4 Ipca Laboratories Product Portfolio
- 4.7.5 Ipca Laboratories Recent Developments
- 4.8 Ishita Active Pharma Ingredients
- 4.8.1 Ishita Active Pharma Ingredients Mesalamine API Company Information
- 4.8.2 Ishita Active Pharma Ingredients Mesalamine API Business Overview
- 4.8.3 Ishita Active Pharma Ingredients Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.8.4 Ishita Active Pharma Ingredients Product Portfolio
- 4.8.5 Ishita Active Pharma Ingredients Recent Developments
- 4.9 Lasa Loboratory
- 4.9.1 Lasa Loboratory Mesalamine API Company Information
- 4.9.2 Lasa Loboratory Mesalamine API Business Overview
- 4.9.3 Lasa Loboratory Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.9.4 Lasa Loboratory Product Portfolio
- 4.9.5 Lasa Loboratory Recent Developments
- 4.10 PharmaZell
- 4.10.1 PharmaZell Mesalamine API Company Information
- 4.10.2 PharmaZell Mesalamine API Business Overview
- 4.10.3 PharmaZell Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.10.4 PharmaZell Product Portfolio
- 4.10.5 PharmaZell Recent Developments
- 4.11 Syntese A/S
- 4.11.1 Syntese A/S Mesalamine API Company Information
- 4.11.2 Syntese A/S Mesalamine API Business Overview
- 4.11.3 Syntese A/S Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.11.4 Syntese A/S Product Portfolio
- 4.11.5 Syntese A/S Recent Developments
- 4.12 Hangzhou Brother
- 4.12.1 Hangzhou Brother Mesalamine API Company Information
- 4.12.2 Hangzhou Brother Mesalamine API Business Overview
- 4.12.3 Hangzhou Brother Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.12.4 Hangzhou Brother Product Portfolio
- 4.12.5 Hangzhou Brother Recent Developments
- 4.13 Lianyungang Fengheng Biopharm
- 4.13.1 Lianyungang Fengheng Biopharm Mesalamine API Company Information
- 4.13.2 Lianyungang Fengheng Biopharm Mesalamine API Business Overview
- 4.13.3 Lianyungang Fengheng Biopharm Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.13.4 Lianyungang Fengheng Biopharm Product Portfolio
- 4.13.5 Lianyungang Fengheng Biopharm Recent Developments
- 4.14 YC Biotech (Jiangsu)
- 4.14.1 YC Biotech (Jiangsu) Mesalamine API Company Information
- 4.14.2 YC Biotech (Jiangsu) Mesalamine API Business Overview
- 4.14.3 YC Biotech (Jiangsu) Mesalamine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.14.4 YC Biotech (Jiangsu) Product Portfolio
- 4.14.5 YC Biotech (Jiangsu) Recent Developments
5 Global Mesalamine API Production by Region
- 5.1 Global Mesalamine API Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mesalamine API Production by Region: 2021-2032
- 5.2.1 Global Mesalamine API Production by Region: 2021-2026
- 5.2.2 Global Mesalamine API Production Forecast by Region (2027-2032)
- 5.3 Global Mesalamine API Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.4 Global Mesalamine API Production Value by Region: 2021-2032
- 5.4.1 Global Mesalamine API Production Value by Region: 2021-2026
- 5.4.2 Global Mesalamine API Production Value Forecast by Region (2027-2032)
- 5.5 Global Mesalamine API Market Price Analysis by Region (2021-2026)
- 5.6 Global Mesalamine API Production and Value, YOY Growth
- 5.6.1 North America Mesalamine API Production Value Estimates and Forecasts (2021-2032)
- 5.6.2 Europe Mesalamine API Production Value Estimates and Forecasts (2021-2032)
- 5.6.3 China Mesalamine API Production Value Estimates and Forecasts (2021-2032)
- 5.6.4 Japan Mesalamine API Production Value Estimates and Forecasts (2021-2032)
6 Global Mesalamine API Consumption by Region
- 6.1 Global Mesalamine API Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 6.2 Global Mesalamine API Consumption by Region (2021-2032)
- 6.2.1 Global Mesalamine API Consumption by Region: 2021-2026
- 6.2.2 Global Mesalamine API Forecasted Consumption by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Mesalamine API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Mesalamine API Consumption by Country (2021-2032)
- 6.3.3 United States
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Mesalamine API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Mesalamine API Consumption by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Russia
- 6.4.8 Spain
- 6.4.9 Netherlands
- 6.4.10 Switzerland
- 6.4.11 Sweden
- 6.4.12 Poland
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Mesalamine API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Mesalamine API Consumption by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 India
- 6.5.7 Australia
- 6.5.8 Taiwan
- 6.5.9 Southeast Asia
- 6.6 South America, Middle East & Africa
- 6.6.1 South America, Middle East & Africa Mesalamine API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East & Africa Mesalamine API Consumption by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 Argentina
- 6.6.5 Chile
- 6.6.6 Turkey
- 6.6.7 GCC Countries
7 Segment by Type
- 7.1 Global Mesalamine API Production by Type (2021-2032)
- 7.1.1 Global Mesalamine API Production by Type (2021-2032) & (t)
- 7.1.2 Global Mesalamine API Production Market Share by Type (2021-2032)
- 7.2 Global Mesalamine API Production Value by Type (2021-2032)
- 7.2.1 Global Mesalamine API Production Value by Type (2021-2032) & (US$ Million)
- 7.2.2 Global Mesalamine API Production Value Market Share by Type (2021-2032)
- 7.3 Global Mesalamine API Price by Type (2021-2032)
8 Segment by Application
- 8.1 Global Mesalamine API Production by Application (2021-2032)
- 8.1.1 Global Mesalamine API Production by Application (2021-2032) & (t)
- 8.1.2 Global Mesalamine API Production Market Share by Application (2021-2032)
- 8.2 Global Mesalamine API Production Value by Application (2021-2032)
- 8.2.1 Global Mesalamine API Production Value by Application (2021-2032) & (US$ Million)
- 8.2.2 Global Mesalamine API Production Value Market Share by Application (2021-2032)
- 8.3 Global Mesalamine API Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
- 9.1 Mesalamine API Value Chain Analysis
- 9.1.1 Mesalamine API Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Mesalamine API Production Mode & Process
- 9.2 Mesalamine API Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Mesalamine API Distributors
- 9.2.3 Mesalamine API Customers
10 Global Mesalamine API Analyzing Market Dynamics
- 10.1 Mesalamine API Industry Trends
- 10.2 Mesalamine API Industry Drivers
- 10.3 Mesalamine API Industry Opportunities and Challenges
- 10.4 Mesalamine API Industry Restraints
11 Report Conclusion
12 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst